Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoidIf approved, Dupixent would be the first and only ...

If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025Priority ...

Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoid If approved, Dupixent would be the first and only targeted medicine to treat BP in the US; FDA decision ...

Sanofi’s Dupixent has been granted FDA priority review for the treatment of bullous pemphigoid (BP), a chronic skin disease. If approved, Dupix ...

Biosimilar Litigations include litigations relating to biosimilar/follow-on products of CDER-listed reference products. Litigations between biosimilar applicants/manufacturers and reference ...

The U.S. Supreme Court’s May 2023 decision in Amgen, Inc. v. Sanofi (Amgen) sent shock waves through the patent world, particularly in the chemical and biotech segments, due to its invalidation ...

Higher fees ensure faster processing by validators. Pending Ethereum transactions can be resolved. Speed up stuck transactions by increasing gas fees or cancel them with a replacement transaction ...

Sanofi, As­traZeneca and two lead­ing trade groups want clar­i­ty around an ap­pel­late de­ci­sion that called for Te­va to delist five in­haler patents from the FDA … ...

TJK has a patent AQP4-IgG with royalties paid, a patent KLHL11, septin 5 and MAP1B IgG pending. ALP reports grants from University of Colorado, grants from Rocky Mountain MS Center, personal fees from ...

The US Patent and Trademark Office told a group of specialized patent judges on Tuesday afternoon they could be expected to return to office as soon as Feb. 24, according to an attendee and several ...

Last Friday, AI startup OpenAI filed a new application to trademark products associated with its brand — “OpenAI” — with the U.S. Patent and Trademark Office (USPTO). Normally, this wouldn ...

L’Oreal OR0.83%increase; green up pointing triangle will sell part of its stake in Sanofi SAN-0.46%decrease; red down pointing triangle back to the French pharmaceutical company for 3 billion ...